Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-25-079602
Filing Date
2025-08-22
Accepted
2025-08-22 09:16:10
Documents
6
Period of Report
2025-08-22

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea0254212-6k_akanda.htm 6-K 10522
2 PRESS RELEASE, DATED AUGUST 22, 2025, ANNOUNCING SHARE CONSOLIDATION ea025421201ex99-1_akanda.htm EX-99.1 12201
3 ARTICLES AND CERTIFICATE OF AMENDMENT OF AKANDA CORP ea025421201ex99-2_akanda.htm EX-99.2 2330
4 GRAPHIC ex99-2_001.jpg GRAPHIC 501915
5 GRAPHIC ex99-2_002.jpg GRAPHIC 564824
6 GRAPHIC ex99-2_003.jpg GRAPHIC 182934
  Complete submission text file 0001213900-25-079602.txt   1745293
Mailing Address 77 KING STREET WEST, SUITE 400 C/O DENTONS CANADA LLP TORONTO A6 M5K 0A1
Business Address 1A, 1B LEAROYD ROAD NEW ROMNEY X0 TN28 8XU 442034889514
AKANDA CORP. (Filer) CIK: 0001888014 (see all company filings)

EIN.: 000000000 | State of Incorp.: A6 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-41324 | Film No.: 251242452
SIC: 2833 Medicinal Chemicals & Botanical Products
(CF Office: 03 Life Sciences)